| Literature DB >> 28176815 |
Masato Karayama1,2, Naoki Inui1,3, Kazutaka Mori1, Masato Kono1, Hironao Hozumi1, Yuzo Suzuki1, Kazuki Furuhashi1, Dai Hashimoto1, Noriyuki Enomoto1, Tomoyuki Fujisawa1, Yutaro Nakamura1, Hiroshi Watanabe3, Takafumi Suda1.
Abstract
The forced oscillation technique provides information concerning respiratory impedance, which comprises resistance and reactance of the respiratory system. However, its relationship with morphological changes of the lungs in chronic obstructive pulmonary disease (COPD) remains unclear. Respiratory impedance and spirometric data were evaluated in 98 patients with COPD and 49 reference subjects. Wall thickness (WT) and airway intraluminal area (Ai) of third- to sixth-generation bronchi, and percentage low-attenuation area with less than -950 HU (%LAA) of lungs were measured using three-dimensional computed tomography. COPD patients had higher respiratory impedance, decreased Ai, and increased %LAA compared with reference subjects. Indices of respiratory resistance and reactance and forced expiratory volume in 1 second (FEV1) were correlated with Ai, and the association between percent predicted FEV1 and Ai was predominant in distal bronchi. The difference in respiratory resistance between 5 Hz and 20 Hz (R5-R20) and FEV1/forced vital capacity ratio (FEV1/FVC) were correlated with WT. The %LAA was correlated with the FEV1/FVC ratio and respiratory reactance. Airway function measurements with the forced oscillation technique provide complementary information to spirometry in COPD.Entities:
Mesh:
Year: 2017 PMID: 28176815 PMCID: PMC5296866 DOI: 10.1038/srep41709
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Patient characteristics.
| All population | Matched population† | |||||
|---|---|---|---|---|---|---|
| COPD (n = 98) | Reference (n = 49) | COPD (n = 70) | Reference (n = 35) | |||
| Age, years | 73 (49–89) | 67 (53–83) | 0.002 | 70 (49–84) | 67 (48–83) | 0.221 |
| Sex: Male | 91 (92.9) | 37 (75.5) | 0.007¶ | 67 (95.7) | 34 (97.1) | 1.000¶ |
| Smoker | 98 (100) | 35 (71.4) | <0.001¶ | 70 (100) | 35 (100) | N.E. |
| Pack-year | 47 (10–250) | 30 (0–120) | <0.001 | 47 (10–250) | 40 (12–120) | 0.654 |
| Height, m | 1.64 (1.42–1.86) | 1.61 (1.44–1.76) | 0.245 | 1.64 (1.49–1.86) | 1.65 (1.47–1.76) | 0.878 |
| Weight, kg | 59.3 (37.4–93.6) | 57.1 (33.3–77.9) | 0.785 | 60.8 (37.4–93.6) | 63.3 (34.9–77.9) | 0.370 |
| BMI, kg/m2 | 22.7 (15.4–33.2) | 22.5 (14.4–28.7) | 0.455 | 22.7 (15.4–33.2) | 22.8 (14.7–28.6) | 0.229 |
| GOLD stage | ||||||
| I/II/III/IV | 20 (20.4)/52 (53.1)/19 (19.4)/7 (7.1) | 14 (20.0)/40 (57.1)/11 (15.7)/5 (7.1) | ||||
| Treatment | ||||||
| LAMA | 19 (19.4) | 13 (18.6) | ||||
| LABA | 9 (9.2) | 7 (10.0) | ||||
| LAMA/LABA | 42 (42.9) | 27 (38.6) | ||||
| ICS/LABA | 20 (20.4) | 0 (0) | ||||
| ICS/LAMA | 1 (1.0) | 1 (1.4) | ||||
| ICS/LAMA/LABA | 5 (5.1) | 3 (4.3) | ||||
Data are expressed as number (%) or median (range). †Propensity score-matched population with age, sex, and smoking status. COPD, chronic obstructive pulmonary disease; BMI, body mass index; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; MMF, maximum mid-expiratory flow rate; GOLD, Global Initiative for Asthma. LABA, long-acting beta 2 agonist; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroid; N.E., not estimated. *Wilcoxon signed-rank test unless otherwise indicated. ¶Fisher’s exact test.
Spirometric data.
| All population | Matched population† | |||||
|---|---|---|---|---|---|---|
| COPD (n = 98) | Reference (n = 49) | COPD (n = 70) | Reference (n = 35) | |||
| FVC (L) | 3.00 (1.14–5.43) | 3.24 (1.80–4.54) | 0.189 | 3.11 (1.14–5.43) | 3.36 (2.19–4.54) | 0.050 |
| FVC, % predicted | 93.1 (54.8–134.9) | 99.8 (80.3–174.7) | 0.009 | 92.6 (57.5–129.7) | 99.2 (80.3–121.4) | 0.034 |
| FEV1 (L) | 1.66 (0.45–3.39) | 2.40 (1.68–3.50) | <0.001 | 1.82 (0.54–3.39) | 2.65 (1.69–3.50) | <0.001 |
| FEV1, % predicted | 64.1 (22.9–114.9) | 97.0 (80.0–163.8) | <0.001 | 65.4 (23.3–112.7) | 95.4 (80.0–110.6) | <0.001 |
| FEV1/FVC (%) | 55.9 (26.6–69.9) | 77.7 (70.0–95.8) | <0.001 | 60.0 (26.6–69.9) | 76.7 (70.0–95.8) | <0.001 |
| MMF (L/S) | 0.66 (0.17–7.10) | 2.08 (1.16–8.59) | <0.001 | 0.78 (0.18–7.10) | 2.2 (1.16–7.41) | <0.001 |
| MMF, %predicted | 23.1 (6.3–83.1) | 76.0 (44.4–135.9) | <0.001 | 28.3 (6.3–83.1) | 70.2 (44.4–135.9) | <0.001 |
Data are expressed as median (range). †Propensity score-matched population with age, sex, and smoking status. Abbreviations are as described in Table 1. *Wilcoxon signed-rank test.
Correlations between airway luminal areas and physiological function tests in patients with COPD.
| 3rd-generation bronchi | 4th-generation bronchi | 5th-generation bronchi | 6th-generation bronchi | |||||
|---|---|---|---|---|---|---|---|---|
| r | r | r | r | |||||
| Spirometry | ||||||||
| FVC, %predicted | 0.349 | <0.001 | 0.291 | 0.005 | 0.385 | <0.001 | 0.418 | <0.001 |
| FEV1, %predicted | 0.375 | <0.001 | 0.392 | <0.001 | 0.474 | <0.001 | 0.548 | <0.001 |
| FEV1/FVC ratio | 0.235 | 0.024 | 0.322 | 0.002 | 0.339 | <0.001 | 0.415 | <0.001 |
| MMF, %predicted | 0.321 | 0.002 | 0.368 | <0.001 | 0.423 | <0.001 | 0.497 | <0.001 |
| Respiratory impedance, whole-breath | ||||||||
| R5 | −0.508 | <0.001 | −0.492 | <0.001 | −0.435 | <0.001 | −0.435 | <0.001 |
| R20 | −0.460 | <0.001 | −0.486 | <0.001 | −0.422 | <0.001 | −0.421 | <0.001 |
| R5-R20 | −0.400 | <0.001 | −0.330 | 0.001 | −0.324 | 0.002 | −0.318 | 0.002 |
| X5 | 0.394 | <0.001 | 0.317 | 0.002 | 0.304 | 0.003 | 0.364 | <0.001 |
| Fres | −0.472 | <0.001 | −0.392 | <0.001 | −0.361 | <0.001 | −0.384 | <0.001 |
| ALX | −0.431 | <0.001 | −0.362 | <0.001 | −0.335 | 0.001 | −0.372 | <0.001 |
Data are expressed as Spearman rank correlation coefficient and p-value. R5, respiratory resistance at 5 Hz; R 20, respiratory resistance at 20 Hz: X5, respiratory reactance at 5 Hz; Fres, resonant frequency; ALX, low-frequency reactance area. The other abbreviations are as described in Table 1.
Correlations between airway wall thickness and physiological function tests in patients with COPD.
| 3rd-generation bronchi | 4th-generation bronchi | 5th-generation bronchi | 6th-generation bronchi | |||||
|---|---|---|---|---|---|---|---|---|
| r | r | r | r | |||||
| Spirometry | ||||||||
| FVC, %predicted | −0.019 | 0.853 | 0.020 | 0.847 | 0.053 | 0.617 | 0.055 | 0.598 |
| FEV1, %predicted | −0.172 | 0.098 | −0.189 | 0.070 | −0.200 | 0.054 | −0.187 | 0.073 |
| FEV1/FVC ratio | −0.269 | 0.009 | −0.320 | 0.002 | −0.326 | 0.001 | −0.323 | 0.002 |
| MMF, %predicted | −0.182 | 0.081 | −0.221 | 0.033 | −0.225 | 0.030 | −0.229 | 0.027 |
| Respiratory impedance, whole-breath | ||||||||
| R5 | 0.257 | 0.013 | 0.294 | 0.004 | 0.150 | 0.150 | 0.093 | 0.375 |
| R20 | 0.176 | 0.092 | 0.212 | 0.041 | 0.056 | 0.595 | −0.015 | 0.885 |
| R5-R20 | 0.358 | <0.001 | 0.384 | <0.001 | 0.313 | 0.002 | 0.276 | 0.007 |
| X5 | −0.220 | 0.034 | −0.218 | 0.036 | −0.140 | 0.180 | −0.115 | 0.272 |
| Fres | 0.264 | 0.010 | 0.308 | 0.003 | 0.205 | 0.048 | 0.206 | 0.048 |
| ALX | 0.275 | 0.008 | 0.301 | 0.003 | 0.181 | 0.082 | 0.170 | 0.103 |
Data are expressed as Spearman rank correlation coefficient and p-value. The other abbreviations are as described in Tables 1 and 3.
Correlations between percentage of low attenuation area and physiological function tests in patients with COPD.
| r | ||
|---|---|---|
| Spirometry | ||
| FVC, %predicted | −0.153 | 0.133 |
| FEV1, %predicted | −0.464 | <0.001 |
| FEV1/FVC ratio | −0.580 | <0.001 |
| MMF, %predicted | −0.453 | <0.001 |
| Respiratory impedance, whole-breath | ||
| R5 | 0.082 | 0.421 |
| R20 | 0.026 | 0.802 |
| R5-R20 | 0.182 | 0.073 |
| X5 | −0.276 | 0.006 |
| Fres | 0.304 | 0.002 |
| ALX | 0.255 | 0.011 |
Data are expressed as Spearman rank correlation coefficient and p-value. %LAA, percentage of low attenuation area <−950 HU; The other abbreviations are as described in Tables 1 and 3.
Respiratory impedance at whole-breath.
| All population | Matched population† | |||||
|---|---|---|---|---|---|---|
| COPD (n = 98) | Reference (n = 49) | COPD (n = 70) | Reference (n = 35) | |||
| R5 (cmH2O/L/s) | 3.17 (0.52–6.38) | 2.46 (0.97–4.96) | <0.001 | 3.11 (0.52–6.38) | 1.86 (0.97–4.96) | <0.001 |
| R20 (cmH2O/L/s) | 2.51 (0.53–4.55) | 2.11 (1.02–4.60) | 0.004 | 2.45 (0.53–4.55) | 1.83 (1.02–4.60) | 0.002 |
| R5-R20 (cmH2O/L/s) | 0.66 (−0.63–2.14) | 0.37 (−0.52–1.86) | <0.001 | 0.53 (−0.63–1.88) | 0.23 (−0.52–1.86) | 0.001 |
| X5 (cmH2O/L/s) | −0.72 (−5.35–0.37) | −0.33 (−2.18–0.24) | <0.001 | −0.59 (−5.35–0.37) | −0.31 (−2.18–0.24) | 0.005 |
| Fres (Hz) | 11.27 (4.00–30.17) | 7.38 (4.16–16.04) | <0.001 | 10.71 (4.00–30.17) | 7.31 (4.16–16.04) | <0.001 |
| ALX (cmH2O/L/s × Hz) | 3.76 (0–51.26) | 1.14 (0.02–14.59) | <0.001 | 2.66 (0–51.26) | 1.06 (0.02–14.59) | 0.002 |
Data are expressed as median (range). †Propensity score-matched population with age, sex, and smoking status. The other abbreviations are as described in Table 3. *Wilcoxon signed-rank test.
Three-dimensional CT imaging of the lungs.
| All population | Matched population† | |||||
|---|---|---|---|---|---|---|
| COPD (n = 98) | Reference (n = 49) | COPD (n = 70) | Reference (n = 35) | |||
| Ai (mm2) | ||||||
| 3rd-generation bronchi | 35.9 (18.2–64.0) | 41.2 (18.9–76.8) | 0.007 | 35.7 (18.2–64.0) | 41.7 (23.2–76.8) | 0.002 |
| 4th-generation bronchi | 9.8 (3.7–20.4) | 11.1 (5.5–25.1) | 0.007 | 9.8 (4.6–18.2) | 11.5 (6.1–25.1) | 0.005 |
| 5th-generation bronchi | 5.8 (2.4–11.7) | 7.1 (3.0–12.0) | <0.001 | 5.8 (2.6–11.6) | 7.1 (3.8–12.0) | <0.001 |
| 6th-generation bronchi | 3.3 (0.9–7.7) | 4.3 (1.7–7.9) | <0.001 | 3.2 (0.9–6.9) | 4.2 (2.3–7.9) | <0.001 |
| WT (mm) | ||||||
| 3rd-generation bronchi | 1.6 (1.2–2.0) | 1.5 (1.3–1.9) | 0.005 | 1.6 (1.2–1.9) | 1.5 (1.3–1.8) | 0.268 |
| 4th-generation bronchi | 1.4 (1.1–1.8) | 1.3 (1.0–1.5) | 0.010 | 1.4 (1.1–1.6) | 1.3 (1.2–1.6) | 0.126 |
| 5th-generation bronchi | 1.2 (0.9–1.5) | 1.2 (1.0–1.4) | 0.085 | 1.2 (0.9–1.5) | 1.2 (1.1–1.4) | 0.407 |
| 6th-generation bronchi | 1.1 (0.9–1.3) | 1.1 (0.9–1.3) | 0.194 | 1.1 (0.9–1.3) | 1.1 (0.9–1.3) | 0.679 |
| %LAA | 41.4 (17.1–64.2) | 29.6 (11.2–51.6) | <0.001 | 40.9 (20.7–64.2) | 31.5 (14.0–51.6) | <0.001 |
Data are expressed as median (range). †Propensity score-matched population with age, sex, and smoking status. COPD, chronic obstructive pulmonary disease; Ai, airway inner luminal area; WT, airway wall thickness; %LAA, percentage of low attenuation area <−950 HU. *Wilcoxon signed-rank test.
Figure 1Three-dimensional CT analysis of the airway.
(A) The image of the airway tree reconstructed by three-dimensional computed tomography. (B) The longitudinal section of the reformatted airway in the multiplanar reconstruction image. (C) Measurement of the airway in the short axis image. Red and green lines indicate the outer and inner edge of the airway, respectively.